2-ethyl-3-methylbenzoic acid | 55262-21-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-ethyl-3-methylbenzoic acid
• 英文别名: 2-Ethyl-3-methylbenzoesaeure
• CAS: 55262-21-0
• 化学式: C₁₀H₁₂O₂
• 分子量: 164.204
• InChiKey: STIPCWMMZXLLNI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-ethyl-3-methylbenzoic acid 在 氯化亚砜 、 N,N-二甲基甲酰胺 作用下， 以 乙酸乙酯 、 甲苯 为溶剂， 反应 20.0h， 生成 (S)-N-(1-azabicyclo[2.2.2]oct-3-yl)-2-butylbenzamide
  参考文献：
  名称：

  2-(Quinuclidin-3-yl)pyrido[4,3-b]indol-1-ones and isoquinolin-1-ones. Potent conformationally restricted 5-HT3 receptor antagonists

  摘要：

  Several series of N-(quinuclidin-3-yl)aryl and heteroaryl-fused pyridones were synthesized and evaluated for 5-HT3 receptor affinity. In the heteroaryl series, 2-(quinuclidin-3-yl)tetrahydropyrido-[4,3-b]indol-1-one (8a) and the 4,5-alkano-bridged analogues (14 and 15) displayed high 5-HT3 receptor affinity with pK(i) values > 9. The (3S)-quinuclidinyl isomers had > 10 fold higher affinity than the (3R)-isomers. In a series of 2-quinuclidin-3-yl)isoquinolin-1-ones, derivatives substituted with small lipophilic groups (25b-e) and with 4,5-alkano-bridges (34-36) also displayed high affinity. In particular, the hexahydro-1H-benz[de]isoquinolinone (S,S)-37 was the highest affinity 5-HT3 receptor ligand prepared (pK(i) 10.4). A number of the high affinity ligands were shown to be potent 5-HT3 receptor antagonists in vivo as determined by inhibition of the B-J reflex in the anesthetized rat. Again, (S,S)-37 was the most active agent tested (ID50 0.02 mug/kg iv), and this compound was also potent in blocking cisplatin-induced emesis in both the ferret and the dog. Computer modeling studies were performed, and previously reported 5-HT3 receptor antagonist pharmacophore models were refined to include a key lipophilic binding domain.

  DOI：

  10.1021/jm00070a008
• 作为产物：
  描述：

  2-溴-3-甲基苯甲酸甲酯 在 5%-palladium/activated carbon 、 氢气 、 palladium diacetate 、 caesium carbonate 、 三苯基膦 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 反应 5.0h， 生成 2-ethyl-3-methylbenzoic acid
  参考文献：
  名称：

  N-杂环卡宾催化的酰胺远程 C(sp3)-H 酰化

  摘要：

  通过自由基介导的 1,5-氢原子转移 (HAT) 机制开发了N-杂环卡宾催化的邻烷基苯甲酰胺的苄基 C-H 酰化和级联环化。与光氧化还原催化不同，这种无光方法能够通过 Breslow 烯醇化物通过单电子转移 (SET) 产生酰胺基自由基。温和的过程可容忍大多数常见的官能团，并以中等到高的收率提供各种二氢异喹啉酮。芳氧基酰胺的电化学特性与基态 SET 假设一致，并提出了一种可能的有机催化转化机制。

  DOI：

  10.1016/j.tetlet.2023.154483

文献信息

• NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS
  申请人：ATOBE Masakazu

  公开号：US20100029690A1

  公开（公告）日：2010-02-04

  Nitrogen-containing heterocyclic compounds represented by the following Formula (1) are provided. The compounds or salts thereof have a strong EP1 antagonistic activity when they are administered to a human or an animal, and they are useful as an effective component of a pharmaceutical agent for prophylaxis and/or treatment of an overactive bladder, for example. Furthermore, they are useful as an effective component of a pharmaceutical agent for the prophylaxis and/or treatment of symptoms including frequent urination, urinary urgency and urinary incontinence.

  提供以下式（1）所代表的含氮杂环化合物。当这些化合物或其盐被给予人类或动物时，它们具有强烈的EP1拮抗活性，并且它们作为预防或治疗过度活动膀胱的药物的有效成分是有用的，例如。此外，它们作为预防或治疗包括频繁排尿、尿急和尿失禁等症状的药物的有效成分是有用的。
• [EN] 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN<br/>[FR] SAXITOXINES 11,13-MODIFIÉES DESTINÉES AU TRAITEMENT DE LA DOULEUR
  申请人：SITEONE THERAPEUTICS INC

  公开号：WO2018183781A1

  公开（公告）日：2018-10-04

  Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium channel function where the compounds are 11,13-modified saxitoxins according to Formula (I): where R4, R4a, R7, R7a, and X2 are as described herein.

  提供的是化合物、包含该化合物的药物组合物、制备该化合物的方法，以及使用该化合物和组合物治疗与电压门控钠通道功能相关的病症的方法，其中所述化合物是根据公式(I)的11,13-修饰的石房蛤毒素：其中R4、R4a、R7、R7a和X2如本文所述。
• [EN] PHENYL-[4-(3-PHENYL-1H-PYRAZOL-4-YL)-PYRIMIDIN-2-Yl)-AMINE DERIVATIVES<br/>[FR] DERIVES DE PHENYL-[4-(3-PHENYL-1H-PYRAZOL-4-YL)-PYRIMIDIN-2-YL)-AMINE
  申请人：NOVARTIS AG

  公开号：WO2004005282A1

  公开（公告）日：2004-01-15

  The invention relates to phenyl-[4-(3-phenyl-1H-pyrazol-4-yl)-pyrimidin-2-yl)-amine derivatives and to processes for the preparation thereof, to pharmaceutical compositions comprising such derivatives and to the use of such derivatives - alone or in combination with one or more other pharmaceutically active compounds - for the preparation of pharmaceutical compositions for the treatment especially of a proliferative disease, such as a tumour.

  这项发明涉及苯基-[4-(3-苯基-1H-吡唑-4-基)-嘧啶-2-基)-胺衍生物，以及其制备方法，包括含有这种衍生物的药物组合物，以及使用这种衍生物 - 单独或与一个或多个其他药用活性化合物结合 - 制备用于治疗增生性疾病，如肿瘤的药物组合物。
• [EN] 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN<br/>[FR] SAXITOXINES MODIFIÉES 11,13 POUR LE TRAITEMENT DE LA DOULEUR
  申请人：SITEONE THERAPEUTICS INC

  公开号：WO2020072835A1

  公开（公告）日：2020-04-09

  Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium channel function where the compounds are 11,13-modified saxitoxins according to Formula (I): (Formula (I)); where R1, and R2 are as described herein.

  本文提供了化合物、包含该化合物的药物组合物、制备该化合物的方法，以及在治疗与电压门控钠通道功能相关的疾病中使用该化合物和组合物的方法，其中该化合物是根据式(I)的11,13-修饰沙雌毒素：(式(I))；其中R1和R2如本文所述。
• 3-thienyl and 3-furanyl pyrrolidine modulators of chemokine receptor activity
  申请人：Merck & Co., Inc.

  公开号：US06303593B1

  公开（公告）日：2001-10-16

  The present invention is directed to pyrrolidine compounds of the formula I: (wherein R1, R2, R3, R4c, R4d, and R4f are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-3 and/or CCR-5.

  本发明涉及式I的吡咯烷化合物（其中R1、R2、R3、R4c、R4d和R4f在此处定义），这些化合物可用作趋化因子受体活性的调节剂。具体而言，这些化合物可用作趋化因子受体CCR-3和/或CCR-5的调节剂。